|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/9/2012 8:30:46 AM
OraSure Technologies Inc. (OSUR)’s OraQuick, which allows people to screen for HIV at home, won’t help slow transmissions of the virus, a public health specialist and an infectious disease doctor said in an editorial. Routine screening in doctors’ offices and clinics is the best way to identify people who don’t know they are infected with HIV, the virus that causes AIDS, and get them to the right care, according to the editorial published today in the Annals of Internal Medicine. OraSure won U.S. approval for the first rapid, at-home HIV screening in July. The saliva test gives results within 20 to 40 minutes without a doctor or laboratory. The test won’t lower barriers to care because of cost and those likely to use it, said A. David Paltiel, a professor of public health and management sciences at Yale University in New Haven, Connecticut, and Rochelle Walensky, an associate professor of medicine at Massachusetts General Hospital in Boston.
|
|
|
|
|
|
|
|
|
|
|